Delta-Fly Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Delta-Fly Pharma has a total shareholder equity of ¥731.0M and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥827.0M and ¥96.0M respectively.
Key information
0%
Debt to equity ratio
JP¥0
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥755.00m |
| Equity | JP¥731.00m |
| Total liabilities | JP¥96.00m |
| Total assets | JP¥827.00m |
Financial Position Analysis
Short Term Liabilities: 4598's short term assets (¥786.0M) exceed its short term liabilities (¥95.0M).
Long Term Liabilities: 4598's short term assets (¥786.0M) exceed its long term liabilities (¥1,000.0K).
Debt to Equity History and Analysis
Debt Level: 4598 is debt free.
Reducing Debt: 4598 has no debt compared to 5 years ago when its debt to equity ratio was 0.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4598 has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 4598 is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.